Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Vyvgart on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Belgium
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Vyvgart (efgartigimod alfa-fcab) is a neonatal Fc receptor (FcRn) blocker approved by the FDA for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
Vyvgart binds to the neonatal Fc receptor, reducing the recycling of IgG antibodies, including the disease-causing autoantibodies responsible for myasthenia gravis. This lowers overall IgG levels, including the pathogenic anti-AChR antibodies that interfere with nerve-to-muscle signal transmission.
Vyvgart is intended for adults with generalized myasthenia gravis who test positive for anti-AChR antibodies, a subset of MG patients with a well-defined autoimmune mechanism targeted by this therapy.
Vyvgart is administered as an intravenous infusion of 10 mg/kg (up to 1,200 mg for patients weighing 120 kg or more) once weekly for four weeks per treatment cycle, with subsequent cycles based on clinical evaluation and a minimum 28-day interval between cycles.
Vyvgart does not carry a formal FDA boxed warning. However, patients and prescribers should be aware of the following important safety information.
Vyvgart may increase susceptibility to infection. Vyvgart should be delayed in patients with an active infection until it has resolved, and patients should be monitored for signs of infection during treatment.
Hypersensitivity reactions, including anaphylaxis and hypotension leading to syncope, have been reported in the postmarketing setting.
Infusion-related reactions have been reported. Patients should be monitored during infusion, with the rate adjusted or infusion interrupted based on severity.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Vyvgart is manufactured and marketed by argenx. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating neurologist confirming generalized myasthenia gravis diagnosis and anti-AChR antibody positivity. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for AChR antibody-positive generalized myasthenia gravis, Vyvgart is sourced through authorized channels and imported under GDP-compliant, cold-chain logistics to preserve product quality throughout transit.
NPP sources Vyvgart directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Vyvgart requires refrigerated storage at 2°C to 8°C, protected from light. NPP maintains a continuous, monitored cold chain throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile cold-chain logistics to the patient's city.
Patients across India can access Vyvgart through NPP's regulated import pathway, with neurology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support neurology care coordination and documentation for Vyvgart access.
Delhi's major hospitals assist patients with prescription support and documentation for Vyvgart.
Bangalore's specialist network offers access coordination for eligible myasthenia gravis patients seeking Vyvgart.
Chennai-based neurology specialists coordinate Vyvgart access alongside comprehensive MG care.
Hyderabad's care institutions support patients pursuing Vyvgart therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Vyvgart.
Pune-based specialists assist with prescription support and Vyvgart treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Vyvgart.
Kochi's specialist units assist patients with the documentation needed for Vyvgart access.
Chandigarh's care centers support Vyvgart treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Vyvgart access process.
Lucknow-based centers assist patients pursuing Vyvgart therapy.
Bhubaneswar's institutions support access to Vyvgart for eligible patients.
Guwahati's specialists help coordinate Vyvgart access for patients across the Northeast.
Patients in other cities across India can also access Vyvgart through NPP's nationwide coordination network.
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
